title: Redirection of T cells with a first fully humanized bispecific CD33-CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells.
authors: C
authors: C
authors: Arndt
authors: M
authors: M
authors: von Bonin
authors: M
authors: M
authors: Cartellieri
authors: A
authors: A
authors: Feldmann
authors: S
authors: S
authors: Koristka
authors: I
authors: I
authors: Michalk
authors: S
authors: S
authors: Stamova
authors: M
authors: M
authors: Bornhäuser
authors: M
authors: M
authors: Schmitz
authors: G
authors: G
authors: Ehninger
authors: M
authors: M
authors: Bachmann
mesh_terms: D018033:Antibodies, Bispecific / Q000276:immunology*; D061067:Antibodies, Monoclonal, Humanized / Q000276:immunology*; D017252:CD3 Complex / Q000276:immunology*; D005434:Flow Cytometry; D006412:Hematopoietic Stem Cells / Q000276:immunology*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000276:immunology / Q000628:therapy*; D063268:Sialic Acid Binding Ig-like Lectin 3 / Q000276:immunology*; D013601:T-Lymphocytes / Q000276:immunology*
chemical_list: D018033:Antibodies, Bispecific; D061067:Antibodies, Monoclonal, Humanized; D017252:CD3 Complex; D063268:Sialic Acid Binding Ig-like Lectin 3